Monalizumab is a monoclonal antibody commercialized by Innate Pharma, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 16 clinical trials, of which 4 were completed, 7 are ongoing, 2 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Monalizumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Monalizumab is expected to reach an annual total of $37 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Monalizumab Overview

Monalizumab (NN-8765, IPH-2201) is under development for the treatment of HER2-positive breast cancer, solid cancers including non-small cell lung cancer and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through intravenous and subcutaneous route. It is a first-in-class humanized IgG4 antibody that targets killer cell lectin-like receptor subfamily C member 1 (KLRC1, NKG2A). It was under development for the treatment of squamous cell carcinoma of the oral cavity, gastro-esophageal junction carcinoma and rheumatoid arthritis, high grade ovarian cancer, endometrial cancer, fallopian tube cancer, cervical cancer, esophageal and peritoneal cancer, hematological cancers like relapsed/refractory chronic lymphocytic leukemia (CLL), recurrent squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, or larynx) colorectal cancer.

Innate Pharma Overview

Innate Pharma is a biotechnology company that develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL); Monalizumab, an immune checkpoint inhibitor targeting solid tumors, head and neck cancer, and Avdoralimab antibody against bullous pemphigoid. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.

The company reported revenues of (Euro) EUR12.1 million for the fiscal year ended December 2021 (FY2021), a decrease of 78.4% over FY2020. The operating loss of the company was EUR47.8 million in FY2021, compared to an operating profit of EUR1.1 million in FY2020. The net loss of the company was EUR52.8 million in FY2021, compared to a net loss of EUR64 million in FY2020.

For a complete picture of Monalizumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.